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It’s now cheaper to print color figures in KI
Have you been concerned in the past about the cost of print-
ing color figures in Kidney International (KI)? KI has listened 
to your concerns and is now offering permanently reduced 
pricing for color figures—a flat fee of $500 per printed page, 
no matter how many color figures are on a page. This pricing 
is more affordable for authors and competitive with other top 
scientific journals. We want to make it easier for authors to 
publish the color figures that demonstrate important scien-
tific findings, and our new pricing reflects our commitment to 
achieving this goal.
38 could not be classified. Urinary NGAL 
levels discriminated between intrinsic 
and prerenal AKI where a urinary 
NGAL level higher than 104 mg/l indi-
cated intrinsic AKI, and an NGAL level 
of 47 mg/l made intrinsic AKI unlikely. 
These studies show that an important 
clinical distinction between AKI and 
prerenal azotemia, which often is quite 
difficult to demonstrate clinically, can 
be achieved with this simple urine test. 
See page 405.
MYO1E and NEIL1 
mutations cause 
nephrotic syndrome
One of the more exciting developments 
in nephrology is the identification of 
mutations in specific genes that lead to 
glomerular disease. As they report in this 
issue, Sanna-Cherchi et al. used the pow-
erful new method of exome sequenc-
ing to identify mutations in two genes 
located in a region of chromosome 15 
in a kindred with nephrotic syndrome. 
Both genes had homozygous disrupt-
ing mutations. One was in MYO1E, a 
cytoskeletal protein, and the other was 
in NEIL1, an endonuclease. Previous 
NGAL, prerenal 
azotemia, and acute 
kidney injury
The search for a biomarker in acute 
kidney injury (AKI) is something of a 
growth industry. Perhaps the most inter-
esting application of such a test would be 
to distinguish between prerenal azotemia 
and acute tubular necrosis. Singer et 
al. tested this idea in 161 hospitalized 
patients by examining urinary neutro phil 
gelatinase-associated lipocalin (NGAL) 
performance with regard to a com posite 
outcome that included progression to a 
higher RIFLE class, dialysis, or death. 
After exclusion of some patients, 75 had 
intrinsic AKI, 32 had prerenal AKI, and 
studies in mice have shown that knock-
out of MYO1E resulted in nephrotic 
syndrome. These mutations were not 
present in other patients with steroid-
resistant nephrotic syndrome or in nor-
mal controls. See page 389.
Better sleep improves 
inflammation in end-
stage renal disease
A Hippocratic aphorism states that 
whenever sleep is laborious, the dis-
ease is deadly. Sleep disturbances in 
end-stage renal disease are common, 
so Chen et al. treated such patients with 
cognitive-behavioral therapy. Using a 
randomized controlled intervention, 
they found that all those treated were 
significantly improved compared with 
the untreated control group. Surpris-
ingly, they found that the treated group 
also had improved levels of C-reactive 
protein, interleukin-18, and oxidized 
low-density lipoprotein. How better 
sleep improves inflammatory markers 
is a real puzzle. At the risk of sound-
ing like a New Age charlatan, we have 
a mind–body problem in our own field! 
See page 415.
